Non-small cell lung cancer prognosis from blood samples
/Tumor DNA in blood may predict response to lung-cancer immunotherapy
Blood tumor mutational burden may give insight into which patients with non-small cell lung cancer (NSCLC) may benefit from therapy with anti-programmed cell death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (anti-PD-L1) monoclonal antibodies, according to Chinese researchers.
A considerable number of patients with advanced cancer may not be able to provide sufficient tissue for molecular testing to guide treatment decisions, Dr. Jie Wang of Peking Union Medical College and colleagues note in JAMA Oncology, online February 28. However, rather than use tumor mutational burden measured by whole-exome sequencing or cancer gene panel, the researchers sought to determine the utility of using circulating tumor DNA in blood.
